对lanreotide和 pasireotide与体静止素受体1的结合方式的结构洞察
Zicheng Zeng1, Qiwen Liao1, Shiyi Gan1
1Kobilka Institute of Innovative Drug Discovery, School of Medicine, the Chinese University of Hong Kong, Shenzhen 518172, China.
高分辨率结构揭示了体静止素受体1 (SSTR1) 如何结合lanreotide和 pasireotide. 这澄清了不同的激活机制,使得改善了针对癌症和神经内分泌疾病的SSTR1向疗法.
科学领域:
- 结构生物学 结构生物学
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 索马托斯塔丁受体1 (SSTR1) 是神经内分泌和瘤疾病的关键治疗标.
- 目前使用索马托斯塔丁类型的治疗方法,如兰列 (Lan) 和利 (Pas),在选择性和疗效方面存在局限性.
研究的目的:
- 为了阐明SSTR1由lanreotide和 pasireotide的独特结合和激活机制.
- 为设计下一代SSTR1向治疗提供结构性见解.
主要方法:
- 高分辨率冷电子显微镜 (cryo-EM) 用于确定SSTR1-连接体复杂结构.
- 生物化学测试和分子动力学模拟以分析结合和激活.
主要成果:
- 获得了SSTR1复合的详细的冷EM结构,并与lanreotide和 pasireotide复合.
- 确定了由每个联结体诱导的SSTR1 Orthosteric口袋中的明显的构造变化.
- 对比分析显示,lanreotide和 pasireotide对SSTR1激活的微妙差异.
结论:
- 这项研究为理解由索马托他他类型的差异性SSTR1激活提供了结构基础.
- 这些发现对于开发具有较低副作用的更有选择性和更有效的SSTR1向药物至关重要.
更多相关视频
10:36In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues
Published on: March 21, 2017
09:49A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
Published on: April 24, 2020
相关概念视频
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
The Two-State Receptor Model
The binding affinity of a drug determines its interaction with...
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Oral Hypoglycemic Agents: Glinides
Dose-Response Relationship: Selectivity and Specificity
Spare Receptors
